News

According to the two companies, the new platform will enable pharmaceutical companies to deliver clinical-based education about new drugs and therapies to physicians worldwide, in an attempt to

Abbott said that the agreement would allow the company to reach its objectives of helping Brazil expand patient access to Kaletra while preserving its intellectual property rights. Although

However, the New Jersey-based generic drugmaker will have to follow this new course of action without its chief executive. The company reported the resignation of its interim CEO,

The subject of the agreement is a technology developed at the Gallo Center and at the University of California San Francisco by Dr Jennifer Whistler and Dr Mark

Greenwich owns exclusive license rights to two anticancer agents – sodium stibogluconate (SSG) and triciribine (TCN-P). According to VioQuest, both treatments are attractive compounds for development, given the

MedicAlert’s Health Enhancement System is designed to help patients keep track of their health. It uses voice and text prompts to guide patients through a three minute procedure

In consideration for Vernalis acquiring the entire issued share capital of Ionix, Vernalis will issue to Ionix’s shareholders approximately 9% of the enlarged issued share capital of Vernalis.

The results of a phase III safety and efficacy study of Bio-E-Gel (bioidentical estradiol transdermal gel) for the treatment of moderate-to-severe hot flashes in menopausal women indicate the

The study evaluated Heartzyme, the new systemic oral enzyme, in a small group of participants. Researchers measured C-reactive protein levels as an indication of the presence of inflammation.